Significant Transactions (Details Textual) - USD ($) |
1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 05, 2022 |
May 23, 2022 |
Oct. 10, 2021 |
Jun. 30, 2022 |
May 31, 2022 |
Jun. 30, 2022 |
Mar. 31, 2022 |
Jun. 30, 2021 |
Jun. 30, 2022 |
Jun. 30, 2021 |
Dec. 31, 2021 |
Oct. 01, 2021 |
|
| Business Acquisition [Line Items] | ||||||||||||
| Exchangeable shares | 1 | 1 | 1 | |||||||||
| Revenues | $ 6,085,881 | $ 4,906,887 | $ 13,036,722 | $ 8,920,911 | ||||||||
| Common stock, shares issued | 36,826,733 | 36,826,733 | 36,826,733 | 36,826,733 | ||||||||
| Preferred stock, par value | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | ||||||||
| Preferred stock, liquidation preference per share | $ 1 | 1 | $ 1 | |||||||||
| Transaction costs | $ 0.5 | |||||||||||
| Sales and marketing costs | 300,000 | |||||||||||
| Product development costs | 200,000 | |||||||||||
| General and administrative expenses | $ 100,000 | |||||||||||
| Acquisition of net income | $ 6,743 | $ 13,317 | ||||||||||
| Exchangeable shares outstanding | 306,852 | |||||||||||
| Reduction of purchase price | 25 | |||||||||||
| Reduction of working capital | $ 1.5 | |||||||||||
| Convertible Notes Amendment description | we and the holders Senior Convertible Notes entered into the Convertible Notes Amendment to add covenants such that (a) we will be subject to a daily cash test beginning on July 1, 2022 of having an available cash balance of at least $7 million, which amount shall be reduced by $1 million on each of the dates at which the aggregate principal due upon the Senior Convertible Notes is equal to or less than $14 million and $11 million, subject in all cases to a minimum of $5 million, and (b) we will establish and maintain bank accounts for each holder and deposit in such accounts an aggregate amount of $7 million with such amount to be released from the accounts only upon the written consent of such holder, provided that $1 million will automatically release from the accounts upon the occurrence of each of the dates at which the aggregate principal due upon the Senior Convertible Notes is equal to or less than $14 million and $11 million, subject to certain conditions. Further the holders of the Senior Convertible Notes waived provisions such that (i) no amortization payments are due and payable for any payments previously required to be made from July 1, 2022 through January 1, 2023, (ii) the holders of the Senior Convertible Notes will not accelerate any previously deferred installment amounts until January 1, 2023 and (iii) the terms of the Senior Convertible Notes which would provide for reset of the conversion price of the Senior Convertible Notes as a result of the issuance of securities under the Unit Offering and instead agree to a reset of the conversion price equal to a per share price of 135% of the Unit Offering price, or $0.3105 per unit. | |||||||||||
| Exercise price (in dollars per share) | $ 0.23 | 0.23 | $ 0.23 | |||||||||
| Common stock offering percentage | 25.00% | 5.00% | ||||||||||
| Cash received in connection with exercise of warrants, shares | 1 | |||||||||||
| Share Price | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||||||||
| Net proceeds | $ 9.3 | |||||||||||
| Convertible notes | $ 7 | $ 7 | $ 7 | |||||||||
| Underwriting Agreement , Description | the Underwriting Agreement, we granted the Underwriter a 45-day option from June 30, 2022 to purchase from the Company (i) additional shares of Common Stock and/or (ii) Common Warrants and/or (iii) Pre-Funded Warrants, in any combination thereof, up to, and not to exceed, 13,043,478 shares of Common Stock or shares of Common Stock underlying Pre-Funded Warrants or Common Warrants, in the aggregate, solely to cover over-allotments, if any. | |||||||||||
| Common stock issued in business combinations | $ 761,178 | $ 940,000 | ||||||||||
| Description of unit offering | (i) 29,382,861 units of the Company consisting of 29,382,861 shares of Common Stock together with Common Stock warrants (the “Common Warrants”) to purchase up to 29,382,861 shares of Common Stock and (ii) 14,095,400 pre-funded units, consisting of 14,095,400 pre-funded warrants (“Pre-Funded Warrants”), with each Pre-Funded Warrant exercisable for one share of Common Stock, together with Common Warrants to purchase up to 14,095,400 shares of Common Stock. The units were sold at a public offering price of $0.23 per unit and the pre-funded units were sold at a public offering price of $0.2299 per pre-funded unit. | |||||||||||
| Pre-Funded Warrants [Member] | ||||||||||||
| Business Acquisition [Line Items] | ||||||||||||
| Exercise price (in dollars per share) | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||||||||
| Underwriter Warrants [Member] | Minimum [Member] | ||||||||||||
| Business Acquisition [Line Items] | ||||||||||||
| Underwriter warrants to purchase | 2,173,913 | 2,173,913 | 2,173,913 | |||||||||
| Warrant [Member] | ||||||||||||
| Business Acquisition [Line Items] | ||||||||||||
| Underwriting Agreement , Description | Underwriting Agreement and upon closing of the Unit Offering, we issued to the Underwriter warrants to purchase up to 2,173,913 shares of Common Stock (the “Underwriter Warrants” and, together with the Common Warrants and the Pre-Funded Warrants, the “Warrants”), which is 5.0% of the aggregate number of Shares and Shares issuable upon exercise of the Pre-Funded Warrants sold in the Unit Offering. The Underwriter Warrants are exercisable at any time and from time to time, in whole or in part, commencing from six months after June 29, 2022 (the "Effective Date") and ending five years from the Effective Date, at a price per share equal to $0.23, which is the public offering price per unit. | |||||||||||
| Warrant [Member] | Maximum [Member] | ||||||||||||
| Business Acquisition [Line Items] | ||||||||||||
| Common stock offering percentage | 9.99% | |||||||||||
| Warrant [Member] | Minimum [Member] | ||||||||||||
| Business Acquisition [Line Items] | ||||||||||||
| Common stock offering percentage | 4.99% | |||||||||||
| Ample Organics [Member] | ||||||||||||
| Business Acquisition [Line Items] | ||||||||||||
| Exchangeable shares | 18,094 | 18,094 | 18,094 | |||||||||
| Aggregate value of exchangeable shares | $ 138,419 | $ 138,419 | $ 138,419 | |||||||||
| Exchangeable shares issued | 291,192 | 291,192 | 291,192 | |||||||||
| Viridian Sciences [Member] | ||||||||||||
| Business Acquisition [Line Items] | ||||||||||||
| Reduction of contingent consideration | $ 6 | |||||||||||
| Stock Consideration in Cash | 1 | |||||||||||
| Cannabis [Member] | ||||||||||||
| Business Acquisition [Line Items] | ||||||||||||
| Cash | $ 5,000,000 | |||||||||||
| Aggregate stock price | $ 8,000,000 | |||||||||||
| Common stock issued in business combinations | $ 12,000,000 | |||||||||||
| 365 Cannabis [Member] | ||||||||||||
| Business Acquisition [Line Items] | ||||||||||||
| Cash | $ 527 | $ 527 | 527 | |||||||||
| Common stock, shares issued | 3,600,000 | |||||||||||
| Value of shares issued for exchangeable shares | 11,060 | |||||||||||
| Reduction of purchase price | 1,500,000 | |||||||||||
| Receivables booked in other current assets | $ 400,000 | $ 400,000 | 400,000 | |||||||||
| Reduction of working capital | $ 160,000 | |||||||||||
| Shares held in escrow, value | $ 940,000 | |||||||||||
| Shares held in escrow | 279,762 | |||||||||||